RGC
Live News • 22h
Regencell Faces Class Action Over Alleged False Statements and Market Manipulation Risk Multiple law firms, including The Gross Law Firm, Bronstein, Gewirtz & Grossman LLC, and Bragar Eagel & Squire, P.C., have filed a class action lawsuit against Regencell Bioscience Holdings Limited.
The complaint alleges Regencell made materially false and misleading statements and omissions that left the company exposed to market manipulation and regulatory scrutiny.
The proposed class covers investors who bought Regencell securities between October 28, 2024 and October 31, 2025, with a court filing deadline of June 23, 2026 for investors seeking to join the action.
This kind of litigation can hang over a stock for an extended period and may influence how investors assess governance, disclosure quality and legal risk around the company.
Anyone who traded shares during the stated class period may want to review their trade history and follow legal updates, since case outcomes and any potential settlements or judgments can affect both sentiment and future liquidity in the stock. Announcement • May 24
Regencell Bioscience Holdings Limited has completed a Follow-on Equity Offering in the amount of $20.000007 million. Regencell Bioscience Holdings Limited has completed a Follow-on Equity Offering in the amount of $20.000007 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 985,222
Price\Range: $20.3
Discount Per Security: $1.3195
Transaction Features: Registered Direct Offering Announcement • May 20
Regencell Bioscience Holdings Limited has filed a Follow-on Equity Offering in the amount of $20.000007 million. Regencell Bioscience Holdings Limited has filed a Follow-on Equity Offering in the amount of $20.000007 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 985,222
Price\Range: $20.3
Discount Per Security: $1.3195
Transaction Features: Registered Direct Offering